156 related articles for article (PubMed ID: 35031227)
1. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
Palomba ML; Till BG; Park SI; Morschhauser F; Cartron G; Marks R; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Popplewell LL
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e443-e451. PubMed ID: 35031227
[TBL] [Abstract][Full Text] [Related]
2. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
3. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
[TBL] [Abstract][Full Text] [Related]
5. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Palomba ML; Cartron G; Popplewell L; Ribrag V; Westin J; Huw LY; Agarwal S; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Morschhauser F
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):504-512. PubMed ID: 35151584
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Herrera AF; Goy A; Mehta A; Ramchandren R; Pagel JM; Svoboda J; Guan S; Hill JS; Kwei K; Liu EA; Phillips T
Am J Hematol; 2020 Jan; 95(1):18-27. PubMed ID: 31621094
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
[TBL] [Abstract][Full Text] [Related]
9. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
[TBL] [Abstract][Full Text] [Related]
12. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P; Zhang H; Johnson R; Martín García-Sancho A; Provencio Pulla M; Trněný M; Yuen S; Tilly H; Kingsley E; Tumyan G; Assouline SE; Auer R; Ivanova E; Kim P; Huang S; Delarue R; Trotman J
J Clin Oncol; 2023 Nov; 41(33):5107-5117. PubMed ID: 37506346
[TBL] [Abstract][Full Text] [Related]
13. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.
Zhai J; Qin Y; Zhu J; Song Y; Shen Z; Du X; Jamois C; Brewster M; Shi Y; Shi J
Br J Clin Pharmacol; 2017 Jul; 83(7):1446-1456. PubMed ID: 28072473
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess G; Hüttmann A; Witzens-Harig M; Dreyling MH; Keller U; Marks R; Ernst T; Pott C; Viardot A; Frontzek F; Trautmann M; Ruckes C; Deuster O; Rosenwald A; Theobald M; Lenz G
Br J Haematol; 2022 Aug; 198(3):482-491. PubMed ID: 35362552
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F; Ghosh N; Lossos IS; Palomba ML; Mehta A; Casasnovas O; Stevens D; Katakam S; Knapp A; Nielsen T; McCord R; Salles G
Blood Cancer J; 2021 Aug; 11(8):147. PubMed ID: 34417444
[TBL] [Abstract][Full Text] [Related]
19. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.
Lim SH; Linton KM; Collins GP; Dhondt J; Caddy J; Rossiter L; Vadher K; Fines K; Rogers LE; Fernando D; Stanton L; Davies AJ; Johnson PWM; Griffiths G
Trials; 2018 Nov; 19(1):619. PubMed ID: 30413184
[TBL] [Abstract][Full Text] [Related]
20. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]